LivaNova (NASDAQ:LIVN) Raised to “Outperform” at Wolfe Research

LivaNova (NASDAQ:LIVN) was upgraded by equities research analysts at Wolfe Research from a “peer perform” rating to an “outperform” rating in a report released on Tuesday,Finviz reports. The brokerage presently has a $60.00 price objective on the stock. Wolfe Research’s target price indicates a potential upside of 36.46% from the stock’s previous close.

Several other equities research analysts have also issued reports on the stock. Stifel Nicolaus lowered their price target on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Robert W. Baird increased their price target on LivaNova from $55.00 to $61.00 and gave the company an “outperform” rating in a research report on Thursday, May 8th. The Goldman Sachs Group decreased their price target on LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. Needham & Company LLC reiterated a “buy” rating and set a $64.00 price objective on shares of LivaNova in a research note on Tuesday, May 13th. Finally, StockNews.com downgraded LivaNova from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 8th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, LivaNova has an average rating of “Buy” and an average target price of $59.29.

LivaNova Price Performance

Shares of LIVN opened at $43.97 on Tuesday. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova has a twelve month low of $32.48 and a twelve month high of $62.04. The stock has a market capitalization of $2.40 billion, a P/E ratio of 104.69 and a beta of 0.84. The company has a 50 day moving average of $38.49 and a 200-day moving average of $44.76.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC raised its stake in LivaNova by 111.7% in the 1st quarter. AQR Capital Management LLC now owns 1,571,295 shares of the company’s stock valued at $60,809,000 after acquiring an additional 829,115 shares during the period. Nuveen LLC acquired a new position in shares of LivaNova in the first quarter valued at $30,954,000. Hotchkis & Wiley Capital Management LLC raised its position in shares of LivaNova by 100.7% in the first quarter. Hotchkis & Wiley Capital Management LLC now owns 1,003,000 shares of the company’s stock valued at $39,398,000 after purchasing an additional 503,350 shares during the period. Freestone Grove Partners LP acquired a new stake in shares of LivaNova during the 4th quarter worth about $23,102,000. Finally, Artisan Partners Limited Partnership acquired a new stake in shares of LivaNova during the 4th quarter worth about $21,340,000. 97.64% of the stock is currently owned by institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.